Midlife women's cardiovascular symptoms: A cluster analysis

Ko, Young Hwii; Chee, Eunice; Chee, Wonshik; Mao, Jun J.

doi:10.1080/07399332.2017.1332626

Cited by 3 publications

(1 citation statement)

References 32 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VMS may also be a risk factor for future cardiovascular disease. 3 , 4 Hormone therapy (HT) is an effective treatment for common VMS, and also for alleviation of some sleep problems during menopause. 5 - 7 Many studies have evaluated the relationships among HT, sleep, and VMS in perimenopausal women.…”

mentioning

confidence: 99%

Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS)

et al. 2018

View full text Add to dashboard Cite

Background This study determined whether two different formulations of hormone therapy [HT: oral conjugated equine estrogens (o-CEE, 0.45 mg/d, n=209), transdermal 17β-estradiol (t-E2; 50μg/d, n=201) plus cyclic progesterone (Prometrium, 200 mg) or placebo (PBO, n=243)] affected sleep domains in participants of the Kronos Early Estrogen Prevention Study (KEEPS). Methods Participants completed the Pittsburgh Sleep Quality Index (PSQI) at baseline and during the intervention at 6, 18, 36, and 48 months. Global sleep quality and individual sleep domain scores were compared between treatments using analysis of covariance, and correlated with vasomotor symptom (VMS) scores using Spearman correlation coefficients. Results Global PSQI scores (mean 6.3; 24% with score >8) were similar across groups at baseline and were reduced (improved sleep quality) by both HT [average change: −1.27 (o-CEE) and −1.32 (t-E2)] when compared to PBO [−0.60; p=0.001 (o-CEE vs PBO]) and p=0.002 (t-E2 vs PBO)]. Domain scores for sleep satisfaction and latency improved with both HT. The domain score for sleep disturbances improved more with t-E2 than o-CEE or PBO. Global sleep scores significantly correlated with VMS severity (rS=0.170, p<0.001 for hot flashes; rS=0.177, p<0.001 for night sweats). Change in scores for all domains except sleep latency and sleep efficiency correlated with change in severity of VMS. Conclusion Poor sleep quality is common in recently menopausal women. Sleep quality improved with both HT formulations. The relationship of VMS with domains of sleep suggests that assessing severity of symptoms and domains of sleep may help direct therapy to improve sleep for postmenopausal women.

show abstract

mentioning

confidence: 99%